Protiva Sues Inex, Sirna in Bid to Establish Ownership of siRNA Delivery Technology | GenomeWeb

Protiva Biotherapeutics this week filed two separate lawsuits against one-time parent company Inex Pharmaceuticals and erstwhile collaborator Sirna Therapeutics, alleging that each company engaged in improper activities that undermined Protiva's key drug-delivery technology.

The legal maneuverings shed new light on a saga involving the RNAi drugs sector's two biggest players and allegations of fraud, theft of trade secrets, and breach of duty and contract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.